- $45.89m
- $50.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.52 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -90.38% | ||
| Return on Equity | -52.15% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Directors
- Rene Sindlev CHM (59)
- Mark Dybul CEO (58)
- Luisa Puche CFO (58)
- Henrik Gronfeldt-Sorensen DRC (49)
- Gregg Alton IND (55)
- Carol Brosgart IND (70)
- Jayne McNicol IND (55)
- Carl Sandler IND (49)
- James Sapirstein IND (60)
- Last Annual
- June 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 18th, 2011
- Public Since
- November 18th, 2014
- No. of Shareholders
- 197
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 230,928,963
- Address
- 2080 Century Park East, Suite 906, LOS ANGELES, 90067
- Web
- Phone
- +1 2127630184
- Auditors
- Sadler, Gibb & Associates, LLC
Upcoming Events for RENB
Q1 2026 Renovaro Inc Earnings Release
Q2 2026 Renovaro Inc Earnings Release
Similar to RENB
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Lunai Bioworks share price?
As of Today at 21:49 UTC, shares in Lunai Bioworks are trading at $0.20. This share price information is delayed by 15 minutes.
How has the Lunai Bioworks share price performed this year?
Shares in Lunai Bioworks last closed at $0.20 and the price had moved by -67.99% over the past 365 days. In terms of relative price strength the Lunai Bioworks share price has underperformed the S&P500 Index by -72.65% over the past year.
What are the analyst and broker recommendations for Lunai Bioworks?
There is no consensus recommendation for this security.
Find out moreWhat is the Lunai Bioworks dividend yield?
Lunai Bioworks does not currently pay a dividend.
Does Lunai Bioworks pay a dividend?
Lunai Bioworks does not currently pay a dividend.
When does Lunai Bioworks next pay dividends?
Lunai Bioworks does not currently pay a dividend.
How do I buy Lunai Bioworks shares?
To buy shares in Lunai Bioworks you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lunai Bioworks?
As of the previous close price of $0.20, shares in Lunai Bioworks had a market capitalisation of $45.89m.
Where are Lunai Bioworks shares listed?
Here are the trading details for Lunai Bioworks:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RENB
What kind of share is Lunai Bioworks?
Based on an overall assessment of its quality, value and momentum Lunai Bioworks is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lunai Bioworks share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Lunai Bioworks share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lunai Bioworks. Over the past six months, its share price has underperformed the S&P500 Index by -78.73%.
As of the last closing price of $0.20, shares in Lunai Bioworks were trading -65.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lunai Bioworks PE Ratio?
The Lunai Bioworks PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lunai Bioworks?
Lunai Bioworks' management team is headed by:
- Rene Sindlev - CHM
- Mark Dybul - CEO
- Luisa Puche - CFO
- Henrik Gronfeldt-Sorensen - DRC
- Gregg Alton - IND
- Carol Brosgart - IND
- Jayne McNicol - IND
- Carl Sandler - IND
- James Sapirstein - IND